Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2/PHASE3
30 participants
INTERVENTIONAL
2021-11-01
2023-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Avatrombopag in the Treatment of Primary Immune Thrombocytopenia(ITP)
NCT04949009
High-dose Dexamethasone Plus Hetrombopag vs High-dose Dexamethasone Alone as Frontline Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Prospective, Multicenter, Randomized Trial
NCT05943691
Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITP
NCT03252457
An Investigation of Dexamethasone With Different Doses in the Management of Immune Thrombocytopenia (ITP)
NCT02153060
High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)
NCT01356511
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AT with 10 mg/d
The patients will be given receive atorvastatin in 10 mg/d for 1 month plus dexamethasone 40mg/d for 4 days.
Atorvastatin 10mg
Atorvastatin will be given in 10 mg po qn for 1 month
Dexamethasone
Dexamethasone will be given in 40mg po qd for 4 days
AT with 20 mg/d
The patients will be given atorvastatin in 20 mg/d for 1 month plus dexamethasone 40mg/d for 4 days.
Atorvastatin 20mg
Atorvastatin will be given in 20 mg po qn for 1 month
Dexamethasone
Dexamethasone will be given in 40mg po qd for 4 days
Dexamethasone
The patients will be given dexamethasone 40mg/d for 4 days.
Dexamethasone
Dexamethasone will be given in 40mg po qd for 4 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atorvastatin 20mg
Atorvastatin will be given in 20 mg po qn for 1 month
Atorvastatin 10mg
Atorvastatin will be given in 10 mg po qn for 1 month
Dexamethasone
Dexamethasone will be given in 40mg po qd for 4 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. within 3 months from diagnosis,untreated patients, may be male orfemale, between the ages of 18 \~ 80 years.
3. To show a platelet count \> 30×10\^9/L and without bleeding manifestations.
Exclusion Criteria
2. Received steroids or other effective therapy for immune thrombocytopenia.
3. Current HIV infection or hepatitis B virus or hepatitis C virus infections.
4. Severe medical condition (lung, hepatic or renal disorder) other than ITP.
5. Unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure, uncontrolled hypertension or cardiac arrhythmia)
6. Female patients who are nursing or pregnant, who may be pregnant, or who contemplate pregnancy during the study period.
7. Have a known diagnosis of other autoimmune diseases, established in the medical history and laboratory findings with positive results for the determination of antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct Coombs test.
8. Patients who are deemed unsuitable for the study by the investigator.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shandong University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ming Hou
Professor and Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ming Hou, Dr
Role: PRINCIPAL_INVESTIGATOR
Shandong University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Qilu hospital, Shandong University
Jinan, Shandong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Atorvastatin in ITP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.